Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
Advertorial

Pharmaceutical product development within the Fujifilm Group

Custom manufacturing of specialty chemicals and APIs.

Fujifilm Wako Pure Chemical Corporation was established as a result of the consolidation between Wako Pure Chemical Corporation and FUJIFILM Fine Chemicals in April 2018. The consolidation enabled us to greatly expand our process development for each production phase, which supports the range from lab scale to commercial manufacture for contract development and manufacturing organisations (CDMOs).

  • Category 5 (OEL: 0.1μg/m3)
  • Containment area
    • 600L(GL) Reactor x 2, 800L(GL) Reactor x 1
    • Filter dryer (0.38m2) x 1, Spiral jet mill
  • General production area
    • 600L(GL) Reactor x 1
  • Containment laboratories for synthesis and analysis
  • ISO9001 and ISO14001
  • Acquired a drug manufacturing Japanese license in 1997 and an FDA license in 2016
  • 150 employees in Hirono plant.

Visit us at CPhI Worldwide – booth number: 120A73.